Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN versus SUPPRELIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN versus SUPPRELIN LA.
SUPPRELIN vs SUPPRELIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH) that acts as a potent inhibitor of gonadotropin secretion. Initially stimulates, then suppresses pituitary gonadotropin release (LH and FSH), leading to decreased testosterone and estrogen production.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
50 mcg subcutaneously once daily for the first month, then 25 mcg subcutaneously once daily for maintenance. Alternatively, 7.5 mg intramuscularly once monthly.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours following subcutaneous administration; this supports once-daily dosing.
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Primarily renal, with approximately 70-80% of histrelin excreted unchanged in urine; biliary/fecal excretion accounts for about 20-30%.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Category C
Category C
GnRH Agonist
GnRH Agonist